Results 261 to 270 of about 950,400 (402)

Emerging Target Discovery Strategies Drive the Decoding of Therapeutic Power of Natural Products and Further Drug Development: A Case Study of Celastrol

Exploration, EarlyView.
Using celastrol as a case study, this review summarizes various target discovery strategies for natural products, including chemical proteomics, protein microarray, degradation‐based protein profiling, proteome‐wide label‐free approaches, network pharmacology, target‐based drug screening, and indirect strategies.
Yanbei Tu, Guiyu Dai, Yanyan Chen, Lihua Tan, Hanqing Liu, Meiwan Chen   +5 more
wiley   +1 more source

Modulation of copper homeostasis and cuproptosis by PDHA1 in acute myeloid leukemia. [PDF]

Discov Oncol
Chen T, Wei N, Lv W, Qu L, Qu Q, Wu C, Ling Y, Liu H, Liu H.   +8 more
europepmc   +1 more source

A case-referent study on acute myeloid leukemia, background radiation and exposure to solvents and other agents

, 1981
Ulf Flodin, Lennart Andersson, Carl-Göran Anjou, Ulla-Britt Palm, Olle Vikrot, Olav Axelson   +5 more
openalex   +2 more sources

A comparative study of dibromomannitol and busulfan in the treatment of chronic myeloid leukemia. A study of cancer and leukemia group B [PDF]

, 1987
Richard T. Silver, Rosemarie Mick, Robert Cooper, Rose Ruth Ellison, R Levy, Kurt Brunner, Joel M. Schwartz, James F. Holland   +7 more
openalex   +1 more source

Phenylethanoid Glycosides in Cistanches: Chemistry, Pharmacokinetic, and Antitumor Properties

Food Frontiers, EarlyView.
This review systematically summarizes the representative PhGs found in CH species, their pharmacokinetic parameters, and primary metabolites in humans and rats. Additionally, it examines the antitumor activities of PhGs in CH and their associated signaling pathways against various malignancies.
Jie Li, Xin‐yue Cao, Jun‐lin Lv, He‐meng Zhang, Qing‐yue Liang, Yu‐shan Ren, Jun Tian, Gui‐cheng Dong   +7 more
wiley   +1 more source

Multimodal spatial proteomic profiling in acute myeloid leukemia. [PDF]

NPJ Precis Oncol
Ly CP, Veletic I, Pacheco CD, Dasdemir E, Jelloul FZ, Ferri-Borgogno S, Basi AV, Gomez JA, Root JL, Reville PK, Jindal S, Basu S, Sharma P, Quesada AE, Bueso-Ramos C, Manshouri T, Cuglievan B, Garcia M, Burks JK, Abbas HA.   +19 more
europepmc   +1 more source

Genomic Profile and Clinical Outcomes in Acute Myeloid Leukemia with Monosomal Karyotype. [PDF]

Int J Mol Sci
Wangulu C, Bahrami Hezaveh E, Zarif M, Zhou Q, Lo W, Wei C, Sibai H, Chang H.   +7 more
europepmc   +1 more source

8;21 Translocation in acute myeloid leukemia an ultrastructural study [PDF]

, 1984
Guido Tricot, A. Broeckaert van Orshoven
openalex   +1 more source

Mechanisms of enhancer‐driven oncogene activation

International Journal of Cancer, EarlyView.
Abstract An aggressive subtype of acute myeloid leukemia (AML) is caused by enhancer hijacking resulting in MECOM overexpression. Several chromosomal rearrangements can lead to this: the most common (inv(3)/t(3;3)) results in a hijacked GATA2 enhancer, and there are several atypical MECOM rearrangements involving enhancers from other hematopoietic ...
Joyce Vriend, Ruud Delwel, Dorien Pastoors   +2 more
wiley   +1 more source

Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions

International Journal of Cancer, EarlyView.
Abstract Chromosomal rearrangements involving the Mixed Lineage Leukemia gene (MLL1, KMT2A) are defining a genetically distinct subset in about 10% of human acute leukemias. Translocations involving the KMT2A‐locus at chromosome 11q23 are resulting in the formation of a chimeric oncogene, where the N‐terminal part of KMT2A is fused to a variety of ...
Florian Perner, Jayant Y. Gadrey, Scott A. Armstrong, Michael W. M. Kühn   +3 more
wiley   +1 more source